Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Bone Marrow Transplant

 

Double Cord Versus Haploidentical Transplants (BMT CTN #1101)
A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo-BM) for Patients With Hematologic Malignancies (BMT CTN #1101)

Investigator: Paul O'Donnell, MD ;   Conditions: Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Burkitt's Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma;    Status: Recruiting;   Study ID: NCT01597778

Crohn's Allogeneic Transplant Study (CATS)
Allogeneic Hematopoietic Cell Transplantation for Patients with Treatment-refractory Crohn's Disease: A Phase 2 Study

Investigator: George B. McDonald ;   Conditions: Crohn's Disease;    Status: Recruiting;   Study ID: NCT01570348

Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones (FHCRC-1655)
Phase I & II Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced MDS, CML, AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant

Investigator: Dr. Gunnar Ragnarsson;   Conditions: Leukemia , Myelodysplastic Syndromes (MDS);    Status: Recruiting;   Study ID: NCT00052520

Non-myeloablative Transplants for CLL and SLL (FH-1840)
Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial

Investigator: Mohamed Sorror, MD, MSc;   Conditions: Leukemia, Lymphoma;    Status: Recruiting;   Study ID: NCT00104858

Chemotherapy w/wo TBI for MDS or AML (FHCRC-1992)
A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplantation in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia.

Investigator: Bart Scott, MD;   Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases;    Status: Closed;   Study ID: NCT00322101

Melphalan followed by SCT for Multiple Myeloma (FHCRC-2004)
A Multi-center Phase III Study of Autologous Transplantation for Patients with Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine with Melphalan 200 mg/m2 + Amifostine

Investigator: Bill Bensinger, MD;   Conditions: Hematologic Malignancies; Multiple Myeloma (MM);    Status: Closed;   Study ID: NCT00217438

Non-myeloablative conditioning and SCT for Non-malignant Inherited Disorders Sans Donor Match (FHCRC-2032)
HLA-Haploidentical Related Marrow Grafts for the Treatment of Immunodeficiency and Other Nonmalignant Disorders Using Conditioning with Low-Dose Cyclophosphamide, 200 cGy TBI and Fludarabine; Postgrafting Immunosuppression Will Consist of a Single Low Dose of Cyclophosphamide, MMF and Tacrolimus.

Investigator: Lauri Burroughs, MD;   Conditions: Immunodeficiency Syndromes, Severe Combined Immunodeficiency Syndrome (SCID);    Status: Recruiting;   Study ID: NCT00358657

Low-dose TBI Dose Escalation Before HCT for CMML, MDS or MPD (FHCRC-2056)
Low-dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders -- A Multi-Center Trial

Investigator: Brenda Sandmaier, MD;   Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Secondary Myelofibrosis;    Status: Recruiting;   Study ID: NCT00397813

Montelukast for Bronchiolitis Obliterans Post Transplant (2317)
Multi-Institutional Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic Stem Cell Transplantation in Children and Adults

Investigator: Paul Martin, MD;   Conditions: Bronchiolitis Obliterans, Chronic Graft-versus-host Disease;    Status: Closed;   Study ID: NCT00656058

Anti-CD45 Antibody followed by Transplant for AML or MDS (2468)
A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (anti-CD45) Antibody followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia , Myelodysplastic Syndrome, Myeloproliferative Syndrome;    Status: Recruiting;   Study ID: NCT01300572

Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) (2531)
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

Investigator: Ann Woolfrey, MD;   Conditions: Hematologic Malignancies;    Status: Recruiting;   Study ID: NCT01351545

Chemotherapy for MDS Patients Prior Donor Stem Cell Transplant (2661)
Initial cytoreductive therapy for myelodysplastic syndrome prior to allogeneic hematopoietic cell transplantation (the ICT-HCT Study)

Investigator: Bart Scott, MD;   Conditions: Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD);    Status: Recruiting;   Study ID: NCT01812252

Computer-Guided Glucose Management Systems for Patients Undergoing Blood and Marrow Transplants (2425)
Use of Computer-Guided Glucose Management Systems for Patients Undergoing Blood and Marrow Transplants (BMT)

Investigator: Eunpi Cho;   Conditions: Patients undergoing bone marrow transplant;    Status: Recruiting;   Study ID: NCT01236885

Gene Modified Donor T-cells Post Stem Cell Transplant (2653)
A Phase1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT

Investigator: Brenda Sandmaier, MD;   Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Lymphoma; Lymphoproliferative Disease; Chronic Graft Versus Host Disease (cGVHD);    Status: Recruiting;   Study ID: NCT01744223

Oral Azacitidine (CC-486) in Subjects with Acute Myeloid Leukemia or Myelodysplastic Syndromes post Allogeneic Transplant (2709)
A Phase 1/2, Dose and Schedule Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Azacitidine (CC-486) in Subjects with Acute Myeloid Leukemia or Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation

Investigator: Bart Scott, MD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic and Myeloproliferative Syndromes;    Status: Recruiting;   Study ID: NCT01835587

Allogeneic HCT Compared to Chemotherapy in Older AML Patients (2368)
Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study

Investigator: Mohamed Sorror, MD, MSc;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS);    Status: Recruiting;   Study ID: NCT01929408

Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
A Study Evaluating BPX-501 T cells and AP1903 for Prevention of GVHD after HLA-Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases

Investigator: Lauri Burroughs, MD;   Conditions: Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Diamond Blackfan Anemia; Fanconi Anemia; Hematologic Malignancies; Lymphoproliferative Disease; Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD); Sickle Cell Anemia; Non-malignant Condition;    Status: Recruiting;   Study ID: NCT02231710

Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis (2067)
Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis

Investigator: George Georges, MD;   Conditions: Autoimmune Diseases, Scleroderma, Systemic Sclerosis;    Status: Recruiting;   Study ID: NCT00622895

Clofarabine and Low-Dose Total-Body Irradiation For AML Patients Undergoing Donor Peripheral Blood Stem Cell Transplant (FHCRC-2430)
A Phase II Study of Optimally Dosed Clofarabine in Combination with Low-Dose TBI to Decrease Relapse Rates after Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients with AML

Investigator: Boglarka Gyurkocza, MD;   Conditions: Acute Myeloid Leukemia (AML);    Status: Recruiting;   Study ID: NCT01252667

Autologous or Syngeneic SCT Followed by Donor SCT for Multiple Myeloma (FHCRC-2070)
Tandem Autologous HCT / Nonmyeloablative Allogeneic HCT from HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients with High-Risk Multiple Myeloma

Investigator: Marco Mielcarek, MD;   Conditions: Graft Versus Host Disease, Multiple Myeloma , Plasma Cell Neoplasm and Plasma Cell Neoplasm;    Status: Recruiting;   Study ID: NCT00793572

Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma (FH 1409)
A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Non-Myeloablative Allogeneic Stem Cell Transplantation for Patients with Relapsed or Refractory Lymphoma - A Multi-Center Trial

Investigator: David Maloney, MD, PhD;   Conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma;    Status: Recruiting;   Study ID: NCT00005803

Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing GVHD for Undergoing Donor Peripheral Blood Stem Cell Transplant (FHCRC-2206)
A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate mofetil (MMF) for Prevention of Acute GVHD after Non-myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation. A Multi-Center Trial

Investigator: Brenda Sandmaier, MD;   Conditions: Hematologic Malignancies;    Status: Recruiting;   Study ID: NCT01251575

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (FHCRC-2448)
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial

Investigator: Brenda Sandmaier, MD;   Conditions: Hematologic Malignancies;    Status: Recruiting;   Study ID: NCT01231412

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant (FHCRC-1825)
Pentostatin and Donor Lymphocyte Infusion for Low Donor T-Cell Chimerism After Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning - A Multicenter Trial

Investigator: Brenda Sandmaier, MD;   Conditions: Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphoid Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma (MM), Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD), Non-Hodgkin's Lymphoma (NHL);    Status: Recruiting;   Study ID: NCT00096161

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (FHCRC-1410)
Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected with HIV-1 Using a Non-Marrow Ablative Conditioning Regimen Containing TBI in Combination with Post-Transplant Immunosuppression with Cyclosporine and Mycophenolate Mofetil

Investigator: Ann Woolfrey, MD;   Conditions: Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Immunodeficiency Syndromes; Malignancies in HIV Patients;    Status: Recruiting;   Study ID: NCT00112593

Azacitidine +/- Gemtuzumab for Post-Transplant Relapse for MDS, CMML and AML (FHCRC-2240)
Treatment of Post-Transplant Relapse and Persistent Disease in Patients with MDS, CMML and AML with Azacitidine +/- Gemtuzumab

Investigator: Bart Scott, MD;   Conditions: Adult Acute Myeloid Leukemia (AML), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes;    Status: Closed;   Study ID: NCT01083706

Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia (FHCRC-2241)
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Investigator: Mohamed Sorror, MD, MSc;   Conditions: Chronic Lymphoid Leukemia (CLL) , Hematologic Malignancies, Hodgkin's Lymphoma, Leukemia , Lymphoma , Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL);    Status: Recruiting;   Study ID: NCT01008462

Natural Killer Cell Therapy Post Non-Myeloablative BMT (FHCRC-2230)
A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation

Investigator: Brenda Sandmaier, MD;   Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases;    Status: Recruiting;   Study ID: NCT00789776

Combination Chemotherapy and Antithymocyte Globulin Followed By SCT for Severe Autoimmune Neurologic Diseases (FHCRC-2260)
A Pilot Study of High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Diseases

Investigator: George Georges, MD;   Conditions: Nonneoplastic Condition;    Status: Recruiting;   Study ID: NCT00716066

Depletion of T Cells From Allogeneic Stem Cell Grafts for the Prevention of GVHD (FHCRC-2222)
A Multi-center Phase II Study of Selective Depletion of CD45RA+ T cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Investigator: Marie Bleakley, MD;   Conditions: Acute Lymphoid Leukemia (ALL);, Acute Myeloid Leukemia (AML), Hematologic Malignancies, Myelodysplastic Syndromes (MDS) Myeloproliferative Syndromes (MPD);    Status: Recruiting;   Study ID: NCT00914940

Unrelated Donor Cord Blood Transplant w/Reduced-intensity Preparative Regimen (FHCRC-2239)
Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen

Investigator: Colleen Delaney, MD, MSc;   Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases;    Status: Recruiting;   Study ID: NCT00723099

Allogeneic HCT for Nonmalignant Inherited Disorders w/ Treosulfan (FHCRC-2256)
Allogeneic Hematopoietic Cell Transplantation for Patients with Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen

Investigator: Lauri Burroughs, MD;   Conditions: Dyskeratosis Congenita, Graft Versus Host Disease, Nonneoplastic Condition, Shwachman-Diamond Syndrome;    Status: Recruiting;   Study ID: NCT00919503

Cord Blood Transplant for Hematological Diseases (FHCRC-2010)
Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen

Investigator: Colleen Delaney, MD, MSc;   Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT00719888

Treosulfan, Fludarabine + TBI w/Unrelated Cord Blood Transplant (FHCRC-2275)
Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen

Investigator: Colleen Delaney, MD, MSc;   Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases;    Status: Recruiting;   Study ID: NCT00796068

Nonmyeloablative HCT for Hematologic Malignancies using Related, HLA-Haploidentical Donors (FHCRC-2372)
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Investigator: Paul O'Donnell, MD, PhD;   Conditions: Hematologic Malignancies;    Status: Recruiting;   Study ID: NCT01028716

Fludarabine Followed by HCT for Primary Immunodeficiencies (FHCRC-2007)
Hematopoietic Cell Transplantation for Treatment of Patients with Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-dose TBI and Fludarabine With or Without Campath®

Investigator: Lauri Burroughs, MD;   Conditions: Immunodeficiency Syndromes, Severe Combined Immunodeficiency Syndrome (SCID);    Status: Open;   Study ID: NCT00553098

Gene Therapy for Fanconi Anemia (2097)
Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)

Investigator: Pamela Becker, MD, PhD;   Conditions: Fanconi Anemia Complementation Group A;    Status: Recruiting;   Study ID: NCT01331018

CD19-specific Donor T Cells for B Cell Malignancies After Allogeneic Transplant (FH 2494)
A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplant

Investigator: Cameron J. Turtle, MD, PhD;   Conditions: Recurrent Adult Acute Lymphoblastic Leukemia;, Recurrent Adult Diffuse Large Cell Lymphoma; , Recurrent Grade 1 Follicular Lymphoma; , Recurrent Grade 2 Follicular Lymphoma; , Recurrent Mantle Cell Lymphoma; , Recurrent Marginal Zone Lymphoma; , Recurrent Small Lymphocytic Lymphoma; , Refractory Chronic Lymphocytic Leukemia;    Status: Recruiting;   Study ID: NCT01475058

Granulocyte Transfusions for Neutropenia
High Dose Granulocyte Transfusions for the Treatment of Infection in Neutropenia: The RING Study (Resolving Infection in Neutropenia With Granulocytes)

Investigator: Michael J. Boeckh, MD;   Conditions: Neutropenia, Infection;    Status: Recruiting;   Study ID: NCT00627393

Low-Dose Prednisone or Methylprednisolone for GVHD (FHCRC-2327)
A Phase III Study to Assess Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease

Investigator: Marco Mielcarek, MD;   Conditions: Graft Versus Host Disease;    Status: Recruiting;   Study ID: NCT00929695

Atorvastatin for Preventing GVHD After Myeloablative Transplant (FHCRC-2545)
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation

Investigator: Marco Mielcarek, MD;   Conditions: Patients Receiving Myeloablative Peripheral Blood Stem Cell Transplantation;    Status: Recruiting;   Study ID: NCT01525407

Atorvastatin for Preventing GVHD After Nonmyeloablative Transplant (FHCRC-2546)
Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation

Investigator: Marco Mielcarek, MD;   Conditions: Patients Receiving Nonmyeloablative Peripheral Blood Stem Cell Transplantation;    Status: Recruiting;   Study ID: NCT01527045